

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT5227798

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
AEGERION PHARMACEUTICALS, INC.	11/08/2018
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	CANTOR FITZGERALD SECURITIES, AS ADMINISTRATIVE AGENT
<b>Street Address:</b>	110 EAST 59TH STREET
<b>City:</b>	NEW YORK
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10022
<b>PROPERTY NUMBERS Total: 6</b>	
<b>Property Type</b>	<b>Number</b>
Patent Number:	10087228
Patent Number:	9879063
Application Number:	15570246
Application Number:	14800537
Application Number:	15882919
Application Number:	15702719
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(312)993-9767
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	3129932647
<b>Email:</b>	zeynep.gieseke@lw.com
<b>Correspondent Name:</b>	ZEYNEP GIESEKE
<b>Address Line 1:</b>	330 NORTH WABASH AVENUE, SUITE 2800
<b>Address Line 2:</b>	LATHAM & WATKINS LLP
<b>Address Line 4:</b>	CHICAGO, ILLINOIS 60611
<b>ATTORNEY DOCKET NUMBER:</b>	062219-0000
<b>NAME OF SUBMITTER:</b>	ZEYNEP GIESEKE
<b>SIGNATURE:</b>	/zg/
<b>DATE SIGNED:</b>	11/08/2018

**Total Attachments: 5**

source=Patent Security Agreement#page1.tif

source=Patent Security Agreement#page2.tif

source=Patent Security Agreement#page3.tif

source=Patent Security Agreement#page4.tif

source=Patent Security Agreement#page5.tif

PATENT SECURITY AGREEMENT dated as of November 8, 2018 (this “Agreement”), among AEGERION PHARMACEUTICALS, INC. (the “Pledgor”) and CANTOR FITZGERALD SECURITIES, as Administrative Agent (in such capacity, the “Administrative Agent”).

Reference is made to the Guarantee and Collateral Agreement dated as of November 8, 2018 (the “Collateral Agreement”), among AEGERION PHARMACEUTICALS, INC., a Delaware corporation, each other Subsidiary Loan Party party thereto and the Administrative Agent, pursuant to which the Pledgor granted to the Administrative Agent, for the benefit of the Secured Parties, a security interest in the Patent Collateral (as defined herein). Pursuant to the Collateral Agreement, the Pledgor agreed execute and deliver this Agreement in order to record the security interest granted to the Administrative Agent with the USPTO. Accordingly, the parties hereto agree as follows:

SECTION 1. Terms. Capitalized terms used in this Agreement and not otherwise defined herein have the meanings specified (including specified by referenced) in the Collateral Agreement. The rules of construction specified in Section 1.01(b) of the Collateral Agreement also apply to this Agreement.

SECTION 2. Grant of Security Interest. As security for the payment or performance, as the case may be, in full of the Secured Obligations, the Pledgor hereby grants to the Administrative Agent, its successors and assigns, for the benefit of the Secured Parties, a security interest (the “Security Interest”) in all of such Pledgor’s right, title and interest in, to and under the United States issued Patents and Patent applications listed on Schedule I attached hereto, together with (a) all reissues, reexaminations, continuations, divisions, continuations-in-part, renewals or extensions thereof, (b) the right to sue or otherwise recover for any past, present and future infringement, dilution, misappropriation, or other violation or impairment thereof, and (c) all Proceeds of the foregoing, including without limitation license fees, royalties, income, payments, claims, damages and proceeds of suit, now or hereafter due and/or payable with respect thereto (the “Patent Collateral”). This Agreement is not to be construed as an assignment of any Patent Collateral.

SECTION 3. Collateral Agreement. The Security Interest granted to the Administrative Agent herein is granted in furtherance, and not in limitation, of the security interest granted to the Administrative Agent pursuant to the Collateral Agreement. The Pledgor hereby acknowledges and affirms that the rights and remedies of the Administrative Agent with respect to the Patent Collateral are more fully set forth in the Collateral Agreement, the terms and provisions of which are hereby incorporated herein by reference as if fully set forth herein. In the event of any conflict between the terms of this Agreement and the Collateral Agreement, the terms of the Collateral Agreement shall govern.

SECTION 4. Termination. Upon the occurrence of the Termination Date or the release of the Pledgor from its obligations under the Collateral Agreement pursuant to Section 7.15 of the Collateral Agreement, the security interest granted herein shall automatically terminate and the Administrative Agent shall execute, acknowledge, and deliver to the Pledgor an instrument in writing in recordable form releasing the collateral pledge, grant, assignment, lien, and security interest in the Patent Collateral under this Agreement.

SECTION 5. Counterparts. This Agreement may be executed in counterparts (and by different parties hereto on different counterparts), each of which shall constitute an original but all of which when taken together shall constitute a single contract. Delivery of an executed signature page to this Agreement by facsimile or other electronic transmission shall be effective as delivery of a manually signed counterpart of this Agreement.

SECTION 6. Governing Law. This Agreement shall be construed in accordance with and governed by the law of the State of New York.

SECTION 7. Recordation. The Pledgor authorizes and requests that the Commissioner for Trademarks record this Agreement with the U.S. Patent and Trademark Office.

SECTION 8. Administrative Agent. Cantor Fitzgerald Securities is entering into this Agreement solely in its capacity as Administrative Agent. The rights, privileges and immunities of the Administrative Agent set forth in the Credit Agreement and the Guarantee and Collateral Agreement shall be incorporated into this Agreement as though fully set forth herein.


[Remainder of this page intentionally left blank]


IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the date first above written.

AEGERION PHARMACEUTICALS, INC., as Pledgor

By: Barbara Chan  
Name: Barbara Chan  
Title: President

CANTOR FITZGERALD SECURITIES, as  
Administrative Agent

By:   
Name: James Buccola  
Title: Head of Fixed Income



[Signature Page to Patent Security Agreement-Aegerion Pharmaceuticals]

**PATENT**  
**REEL: 047447 FRAME: 0931**

Schedule I to the  
Patent Security Agreement

**PATENT COLLATERAL**

Title of Invention	Jurisdiction	Status	Application No.	Filing Date/ National Entry	Patent No.	Grant Date	Assignee/ Applicant
Compound Impurities and Methods of Detecting Same	United States	Pending	15/570246	October 27, 2017			Aegerion Pharmaceuticals
Highly Soluble Lepins	United States	Granted	14/703523	May 4, 2015	10087228	October 2, 2018	Aegerion Pharmaceuticals, Inc.
Engineered Polypeptides Having Enhanced Duration of Action	United States	Pending	14/800537	July 15, 2015			Aegerion Pharmaceuticals, Inc.
Engineered Polypeptides Having Enhanced Duration of Action and Reduced Immunogenicity	United States	Granted	14/837705	August 27, 2015	9879063	January 30, 2018	Aegerion Pharmaceuticals, Inc.
Engineered Polypeptides Having Enhanced Duration of Action and Reduced Immunogenicity	United States	Pending	15/882919	January 29, 2018			Aegerion Pharmaceuticals, Inc.
Methods of Detecting Anti-Leptin Neutralizing Antibodies	United States	Pending	15/702719	September 12, 2017			Aegerion Pharmaceuticals, Inc.

**PATENT**

**REEL: 047447 FRAME: 0932**

**RECORDED: 11/08/2018**